Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Dyne Therapeutics, Inc. (DYN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 107.48 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2023-03-02
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2022-12-31 was 39.64K shares.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2022-09-30 was 14.94K shares.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 107.48K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2022-12-31 | 39.64K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 54.58K shares derived: sum of 2 quarters · filed 2023-03-02 | 107.48K shares 10-K · filed 2023-03-02 | |
| 2022-09-30 | 14.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 67.84K shares 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 52.90K shares 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |